Cedars-Sinai Medical Center
- Type
- Teaching hospital
- Where
- West Hollywood, CA
- Medicare CCN
- 050625
- Received
- $25,959,593 in 1,319 records, 2021 ($7,042,698 general, $18,916,894 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Cedars-Sinai Medical Center Fuzzy (name and state)
- Business registration: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Nonprofit contractor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying registrant: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: Cedars-Sinai Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 322 | $7,042,698 |
| 2021 | Research payment | 997 | $18,916,894 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 997 | $18,916,894 |
| Royalty or License | 15 | $4,467,564 |
| Grant | 82 | $1,284,996 |
| Education | 68 | $437,120 |
| Consulting Fee | 4 | $384,200 |
| Space rental or facility fees (teaching hospital only) | 67 | $138,325 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 14 | $128,068 |
| Long term medical supply or device loan | 24 | $102,222 |
| Debt forgiveness | 40 | $98,313 |
| Charitable Contribution | 1 | $1,000 |
| Gift | 7 | $886 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $876,529 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Advanced BRCA-mutated Breast Cancers | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $616,122 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab neoHIP | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $458,951 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Neoadjuvant Her2-targeted Therapy and Immunotherapy with Pembrolizumab neoHIP | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $359,227 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $183,111 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $104,249 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $93,184 | Research payment | In-kind items and services | Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $52,921 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $50,336 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Single Arm, Open Label Phase 1b,2 Study of Tucatinib in Combination with Trastuzumab and Pembrolizumab in Women with HER | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $48,098 | Research payment | In-kind items and services | Drug, ONCOLOGY | A PHASE 1, MULTIPLE-DOSE, DOSE-ESCALATION TRIAL OF PT2385 TABLETS, A HIF-2 INHIBITOR, IN PATIENTS WITH ADVANCED CLEAR C | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $40,821 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $29,046 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $20,996 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,848 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutatio | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $17,190 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2021 |
| 2021-12-31 | Intuitive Surgical, Inc. | $16,840 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,801 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $10,367 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,093 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $9,466 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $8,250 | Research payment | Cash or cash equivalent | CSMC2020MRIPR017Li | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $6,252 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Subjects with High Risk Non-muscl | 2021 |
| 2021-12-31 | Brahms GmbH | $6,000 | Research payment | In-kind items and services | BRAHMS KRYPTOR compact PLUS (instrument) Device, Kryptor instrument | Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $5,651 | Research payment | Cash or cash equivalent | CSMC2021MRIPR941IPR932Li | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $5,642 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose C | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $5,057 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | Immunogenicity of Nonavalent HPV Vaccine Administered Prior To Living Donor Renal Transplantation in Adult Women A Prosp | 2021 |
| 2021-12-31 | Shockwave Medical, Inc | $5,000 | Long term medical supply or device loan | In-kind items and services | Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Device, Lithoplasty | 2021 | |
| 2021-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,635 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2021 |
| 2021-12-31 | AngioDynamics, Inc. | $4,333 | Education | In-kind items and services | Solero Device, Oncology | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $4,249 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $3,931 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,387 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,308 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $3,000 | Research payment | Cash or cash equivalent | CSMC2020MRIPR794IPR992Li | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,856 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,779 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-12-31 | ABBVIE INC. | $2,760 | Research payment | In-kind items and services | An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure | 2021 | |
| 2021-12-31 | Intuitive Surgical, Inc. | $2,720 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Intuitive Surgical, Inc. | $2,720 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $2,578 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P | 2021 |
| 2021-12-31 | Rapid Medical Ltd | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TIGERTRIEVER 17 REVASCULARIZATION DEVICE Device, cardiovascular | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,194 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,194 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,162 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $2,117 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Linvatec Corporation | $1,973 | Long term medical supply or device loan | In-kind items and services | MICROPOWER Device, ORTHOPEDIC SURGERY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,923 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,890 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination with Paclitaxel or Pe | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,836 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,818 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,577 | Education | In-kind items and services | LED POWER Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,524 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination with Paclitaxel or Pe | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $1,391 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in P | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,308 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $1,252 | Research payment | In-kind items and services | A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Ch | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $1,203 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $1,058 | Research payment | In-kind items and services | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2021 | |
| 2021-12-31 | Medline Industries LP | $1,042 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | KARL STORZ Endoscopy-America | $971 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | ABBVIE INC. | $927 | Research payment | In-kind items and services | A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $898 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $898 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | ABBVIE INC. | $849 | Research payment | In-kind items and services | A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABB | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $750 | Research payment | Cash or cash equivalent | CSMC2019MRIPR785Xie | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $717 | Research payment | Cash or cash equivalent | Biograph mCT X-4R Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | Evaluation of new method of cardiac PETCT registration | 2021 |
| 2021-12-31 | Medline Industries LP | $617 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | KARL STORZ Endoscopy-America | $612 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $536 | Research payment | In-kind items and services | LYNPARZA Biological, ONCOLOGY | A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutatio | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $525 | Research payment | In-kind items and services | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $483 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $446 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $427 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $414 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $389 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $375 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $348 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Paragonix Technologies, Inc. | $315 | Gift | In-kind items and services | Sherpacool Device, Cardiology | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $292 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $277 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $274 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $263 | Debt forgiveness | In-kind items and services | 2021 | ||
| 2021-12-31 | KARL STORZ Endoscopy-America | $208 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $186 | Research payment | In-kind items and services | n.a. Device, ANESTHESIOLOGY | Evaluation of Utility of Bronchoscopy After Urgent Intubation | 2021 |
| 2021-12-31 | KARL STORZ Endoscopy-America | $125 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $125 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $116 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Stryker Corporation | $116 | Long term medical supply or device loan | In-kind items and services | SURGICOUNT Device, SURGICAL | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $92 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Stryker Corporation | $64 | Long term medical supply or device loan | In-kind items and services | SURGICOUNT Device, SURGICAL | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $53 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Stryker Corporation | $50 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | KARL STORZ Endoscopy-America | $47 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $45 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Stryker Corporation | $24 | Long term medical supply or device loan | In-kind items and services | SURGICOUNT Device, SURGICAL | 2021 | |
| 2021-12-31 | Stryker Corporation | $24 | Long term medical supply or device loan | In-kind items and services | SURGICOUNT Device, SURGICAL | 2021 | |
| 2021-12-31 | Stryker Corporation | $24 | Long term medical supply or device loan | In-kind items and services | SURGICOUNT Device, SURGICAL | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $22 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $21 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | Stryker Corporation | $13 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-31 | KARL STORZ Endoscopy-America | $12 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $10 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $8 | Education | In-kind items and services | Device, LAPAROSCOPY | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $7 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2021 | |
| 2021-12-29 | Merck Sharp & Dohme LLC | $105,617 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2021 |
| 2021-12-29 | Abbott Laboratories | $610 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-29 | Abbott Laboratories | $326 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-28 | ABBVIE INC. | $8,052 | Research payment | Cash or cash equivalent | Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor | 2021 | |
| 2021-12-23 | Bayer Healthcare Pharmaceuticals Inc. | $4,952 | Research payment | Cash or cash equivalent | Non-Covered | Combo with PD-1 inhibitor | 2021 |
| 2021-12-23 | PFIZER INC. | $4,816 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EF | 2021 | |
| 2021-12-22 | Alkermes, Inc. | $31,280 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2021 | |
| 2021-12-22 | Intercept Pharmaceuticals, Inc. | $7,439 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-12-22 | Gilead Sciences, Inc. | $1,808 | Research payment | Cash or cash equivalent | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | 2021 | |
| 2021-12-22 | Gilead Sciences, Inc. | $1,547 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2021 | |
| 2021-12-22 | Concordia Laboratories Inc. | $280 | Research payment | Cash or cash equivalent | PDT Registry | 2021 | |
| 2021-12-21 | Boston Scientific Corporation | $9,253 | Research payment | Cash or cash equivalent | Cryoablation Device, Breast Cancer | A Single Arm Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation in Women with Hormone Receptor-Negat | 2021 |
| 2021-12-21 | Bausch Health US, LLC | $8,791 | Research payment | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | An Open Label Pilot study of Rifaximin in the Treatment of Non-Alcoholic Steatohepatitis | 2021 |
| 2021-12-21 | Janssen Biotech, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | STELARA Biological, Immunology | 2021 | |
| 2021-12-21 | Janssen Research & Development, LLC | $1,452 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-12-21 | Takeda Pharmaceuticals U.S.A., Inc. | $780 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PERIOD CROSSOVER, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLE | 2021 | |
| 2021-12-20 | Boston Scientific Corporation | $170,233 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | PROTECTED TAVR: STROKE PROTECTION WITH SENTINEL DURING TRANS | 2021 |
| 2021-12-20 | Gilead Sciences, Inc. | $42,056 | Research payment | Cash or cash equivalent | A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combinati | 2021 | |
| 2021-12-20 | Boston Scientific Corporation | $15,237 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE: TRANSCATHETER REPLACEMENT OF STENOTIC AORTIC VA | 2021 |
| 2021-12-20 | Exelixis Inc. | $4,100 | Research payment | Cash or cash equivalent | CABOMETYX Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2021 |
| 2021-12-17 | Siemens Medical Solutions USA, Inc. | $10,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-17 | Siemens Medical Solutions USA, Inc. | $2,500 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-17 | Epizyme, Inc. | $2,280 | Research payment | Cash or cash equivalent | TAZVERIK Drug, ONCOLOGY | A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-S | 2021 |
| 2021-12-17 | Bayer Healthcare Pharmaceuticals Inc. | $2,200 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Vitrakvi Drug, Oncology | 2021 | |
| 2021-12-17 | Merck Sharp & Dohme LLC | $1,860 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Subjects with High Risk Non-muscl | 2021 |
| 2021-12-17 | MEDIVATION LLC. | $1,835 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2021 |
| 2021-12-17 | W. L. Gore & Associates, Inc. | $1,024 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2021 |
| 2021-12-17 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | Micra Device, Pacemakers | PSR-CVG | 2021 |
| 2021-12-17 | Epizyme, Inc. | $54 | Research payment | Cash or cash equivalent | TAZVERIK Drug, ONCOLOGY | A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-S | 2021 |
| 2021-12-17 | Epizyme, Inc. | $39 | Research payment | Cash or cash equivalent | TAZVERIK Drug, ONCOLOGY | A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-S | 2021 |
| 2021-12-16 | Cook Research Incorporated | $81,270 | Research payment | Cash or cash equivalent | Gastral Jejunal Feeding Tubes Study | 2021 | |
| 2021-12-16 | Janssen Research & Development, LLC | $26,380 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-12-16 | PROGENICS PHARMACEUTICALS, INC. | $4,600 | Research payment | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultra | 2021 |
| 2021-12-16 | Zimmer Biomet Holdings, Inc. | $4,550 | Research payment | Cash or cash equivalent | ROSA-Knee Device, Knees | The accuracy and reproducibility of Zimmer Biomet ROSA in helping surgeons achieve a target hip-knee-angle | 2021 |
| 2021-12-16 | Zimmer Biomet Holdings, Inc. | $4,550 | Research payment | Cash or cash equivalent | ROSA-Knee Device, Knees | Early radiographic and clinical outcomes in low volume surgeons performing robotic assisted total knee arthroplasty comp | 2021 |
| 2021-12-16 | Janssen Research & Development, LLC | $2,979 | Research payment | Cash or cash equivalent | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2021 | |
| 2021-12-16 | ABBVIE INC. | $2,259 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the | 2021 |
| 2021-12-16 | Abbott Laboratories | $1,350 | Consulting Fee | Cash or cash equivalent | Dragonfly OCT Device, Vascular | 2021 | |
| 2021-12-16 | Cook Research Incorporated | $525 | Research payment | Cash or cash equivalent | Gastral Jejunal Feeding Tubes Study | 2021 | |
| 2021-12-16 | SEAGEN INC. | $397 | Research payment | Cash or cash equivalent | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n | 2021 | |
| 2021-12-16 | Eli Lilly and Company | $21 | Research payment | In-kind items and services | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2021 | |
| 2021-12-15 | Karyopharm Therapeutics Inc. | $56,780 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | Selinexor in liposarcoma: molecular mechanisms, drug combo and biomarkers | 2021 |
| 2021-12-15 | Gilead Sciences, Inc. | $11,660 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 1b/2a study in A Phase 1b/2a Study in Participants with Early Stage COVID-19 to Evaluate the Safety, Efficacy, a | 2021 |
| 2021-12-15 | Kaneka Medical America LLC | $6,531 | Consulting Fee (12 payments) | Cash or cash equivalent | LIPOSORBER Device, Lipid Apheresis | 2021 | |
| 2021-12-15 | Intercept Pharmaceuticals, Inc. | $2,472 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2021 |
| 2021-12-15 | Gilead Sciences, Inc. | $2,396 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 1b/2a study in A Phase 1b/2a Study in Participants with Early Stage COVID-19 to Evaluate the Safety, Efficacy, a | 2021 |
| 2021-12-15 | BONE SUPPORT AB | $730 | Research payment | Cash or cash equivalent | CERAMENT G Device, Bone void and fracture | A Prospective, Randomized Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibia | 2021 |
| 2021-12-15 | Medtronic, Inc. | $268 | Research payment | Cash or cash equivalent | INTERSTIM Device, Sacral Nerve Stimulation | ELITE | 2021 |
| 2021-12-14 | Novartis Pharmaceuticals Corporation | $13,000 | Research payment | Cash or cash equivalent | Drug | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACO | 2021 |
| 2021-12-14 | Abbott Laboratories | $3,547 | Research payment | In-kind items and services | Alinity i System Device, Core Diagnostics | ARS-CoV-2 IgG Quantitative Assay System Suitability Study on Alinity i | 2021 |
| 2021-12-14 | Daiichi Sankyo Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | 2021 | |
| 2021-12-14 | Abbott Laboratories | $832 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-14 | Abbott Laboratories | $400 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-12-10 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-12-09 | PFIZER INC. | $41,028 | Research payment | In-kind items and services | TALZENNA Drug, ONCOLOGY | A PHASE 1 OPEN LABEL CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMU | 2021 |
| 2021-12-09 | Blueprint Medicines Corporation | $26,550 | Research payment | Cash or cash equivalent | BLU-945-1101 | 2021 | |
| 2021-12-09 | Blueprint Medicines Corporation | $6,644 | Research payment | Cash or cash equivalent | BLU-945-1101 | 2021 | |
| 2021-12-09 | Blueprint Medicines Corporation | $2,600 | Research payment | Cash or cash equivalent | BLU-945-1101 | 2021 | |
| 2021-12-09 | Blueprint Medicines Corporation | $2,000 | Research payment | Cash or cash equivalent | BLU-945-1101 | 2021 | |
| 2021-12-09 | Blueprint Medicines Corporation | $1,430 | Research payment | Cash or cash equivalent | BLU-945-1101 | 2021 | |
| 2021-12-09 | Blueprint Medicines Corporation | $1,300 | Research payment | Cash or cash equivalent | BLU-945-1101 | 2021 | |
| 2021-12-08 | Musculoskeletal Transplant Foundation Inc. | $15,844 | Research payment | Cash or cash equivalent | Elbow Ulnar Collateral Ligament Reconstruction with Knee Collateral Ligament allograft a biomechanical study | 2021 | |
| 2021-12-08 | Gilead Sciences, Inc. | $6,550 | Research payment | Cash or cash equivalent | A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies | 2021 | |
| 2021-12-08 | United Therapeutics Corporation | $2,392 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | ADAPT - A PATIENT REGISTRY OF THE REAL-WORLD USE OF ORENITRAM | 2021 |
| 2021-12-08 | PFIZER INC. | $384 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EF | 2021 | |
| 2021-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $194 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2021 | |
| 2021-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $116 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2021 | |
| 2021-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $32 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2021 | |
| 2021-12-07 | TransMedics, Inc. | $26,300 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | OCS-CAR0824020 | 2021 |
| 2021-12-06 | Takeda Pharmaceuticals U.S.A., Inc. | $81,223 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-06 | Edwards Lifesciences Corporation | $23,050 | Research payment | Cash or cash equivalent | The SURPASS Study 2017-15 | 2021 | |
| 2021-12-06 | Gilead Sciences, Inc. | $1,000 | Research payment | Cash or cash equivalent | Harvoni Drug, HCV | A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for H | 2021 |
| 2021-12-06 | Boston Scientific Corporation | $681 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | ASAP TOO | 2021 |
| 2021-12-06 | ZOLL Medical Corporation | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, DEFIBRILLATOR | 2021 | |
| 2021-12-02 | Alexion Pharmaceuticals, Inc. | $10,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-02 | IBSA Institut Biochimique SA | $5,000 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-02 | PFIZER INC. | $3,445 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2021 |
| 2021-12-02 | AstraZeneca Pharmaceuticals LP | $1,500 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-02 | PFIZER INC. | $975 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2021 |
| 2021-12-01 | Merck Sharp & Dohme LLC | $144,714 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Pilot Study of Immune Checkpoint Inhibition with Pembrolizumab in Advanced BRCA-mutated Breast Cancers | 2021 |
| 2021-12-01 | PFIZER INC. | $18,861 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2021 |
| 2021-12-01 | Gilead Sciences, Inc. | $7,076 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 1b/2a study in A Phase 1b/2a Study in Participants with Early Stage COVID-19 to Evaluate the Safety, Efficacy, a | 2021 |
| 2021-12-01 | PROGENICS PHARMACEUTICALS, INC. | $4,600 | Research payment | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultra | 2021 |
| 2021-12-01 | Roche Products Limited | $2,982 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2021 |
| 2021-11-30 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2021 |
| 2021-11-29 | Amgen Inc. | $20,235 | Research payment | In-kind items and services | Repatha Biological, Cardiology | Effect of evolocumab on coronary artery plaque volume and composition by coronary CTA (CCTA) and microcalcification by F | 2021 |
| 2021-11-29 | Medtronic, Inc. | $3,935 | Research payment | Cash or cash equivalent | INTERSTIM Device, Sacral Nerve Stimulation | ELITE | 2021 |
| 2021-11-29 | Janssen Research & Development, LLC | $3,080 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2021 | |
| 2021-11-26 | Boston Scientific Corporation | $18,507 | Research payment | Cash or cash equivalent | Cryoablation Device, Breast Cancer | A Single Arm Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation in Women with Hormone Receptor-Negat | 2021 |
| 2021-11-26 | Ethicon Inc. | $6,089 | Research payment | Cash or cash equivalent | Neuwave Device, Ablation System | A Multi Center Observational Registry to Develop Ablation Parameter Guidance for Microwave Liver Ablation of Soft Tissue | 2021 |
| 2021-11-26 | Genentech, Inc. | $4,643 | Research payment | Cash or cash equivalent | Actemra Biological, Immunology | PHIB STUDY OF RO6958688 AND ATEZOLIZUMAB IN 3L MSS MCRC PTS AFTER PRETX WITH OBINUTUZUMAB | 2021 |
| 2021-11-26 | PFIZER INC. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2021 | |
| 2021-11-25 | Janssen Research & Development, LLC | $5,171 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2021 | |
| 2021-11-24 | Edwards Lifesciences Corporation | $93,231 | Research payment | Cash or cash equivalent | TRISCEND II Pivotal (2020-05) | 2021 |
The latest 200 records of 1,319.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In West Hollywood, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) West Hollywood, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 34,884 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 35,757 | 10,014,009 | 39,538,223 |
| Median age B01002 | 40.0 | 38.2 | 37.9 |
| Under 18 B01001 | 3.6% | 20.6% | 22.0% |
| 65 and over B01001 | 16.8% | 15.2% | 15.7% |
| Households B11001 | 22,920 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 23.6% | 33.4% | 27.0% |
| Median household income B19013 | $96,995 | $90,112 | $99,122 |
| Median family income B19113 | $126,364 | $101,573 | $113,346 |
| Per capita income B19301 | $90,080 | $45,792 | $49,513 |
| Poverty rate B17001 | 12.9% | 13.7% | 12.0% |
| Unemployment rate B23025 | 8.9% | 7.3% | 6.6% |
| Civilian labor force B23025 | 25,818 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 27.1 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 64.2% | 36.0% | 37.1% |
| Housing units B25001 | 26,079 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 19.8% | 45.9% | 55.9% |
| Renters B25003 | 80.2% | 54.1% | 44.1% |
| Median home value B25077 | $924,800 | $834,200 | $734,700 |
| Median gross rent B25064 | $2,091 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 69.5% | 24.7% | 33.8% |
| Black B03002 | 4.3% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 13.1% | 48.4% | 40.2% |
| Asian B03002 | 6.1% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in West Hollywood, CA.
Comments